Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare genetic disease reported in two siblings of consanguineous Arab parents and is characterized by cystic fibrosis, gastritis associated with Helicobacter pylori, folate deficiency megaloblastic anemia, and intellectual disability. There have been no further descriptions in the literature since 1991.
Biomarker and diagnostic research for cystic fibrosis-gastritis-megaloblastic anemia syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for cystic fibrosis-gastritis-megaloblastic anemia syndrome.
123 publications have been identified in PubMed for cystic fibrosis-gastritis-megaloblastic anemia syndrome. Research spans Review / Meta-Analysis (64%), Basic Science / Preclinical (14%), and Case Report / Case Series (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 72 | 64% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 9:07 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research |
16 |
14% |
Patient case studies | 12 | 11% |
Disease patterns and progression | 7 | 6% |
Other research | 2 | 2% |
Testing and diagnosis research | 2 | 2% |
Clinical study results | 1 | 1% |
Balbi M (2026). [PMID: 41764196](https://pubmed.ncbi.nlm.nih.gov/41764196/). *Cell Death Discov*. [Basic Science / Preclinical]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Diagnostic / Biomarker]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
El Athmani O (2026). [PMID: 41841155](https://pubmed.ncbi.nlm.nih.gov/41841155/). *Cureus*. [Case Report / Case Series]
Niazi M (2026). [PMID: 42147655](https://pubmed.ncbi.nlm.nih.gov/42147655/). *Cureus*. [Case Report / Case Series]
Liu Z (2026). [PMID: 41492049](https://pubmed.ncbi.nlm.nih.gov/41492049/). *J Clin Ultrasound*. [Case Report / Case Series]
Patel R (2025). [PMID: 40204117](https://pubmed.ncbi.nlm.nih.gov/40204117/). *J Neuroradiol*. [Basic Science / Preclinical]
Paller AS (2025). [PMID: 40184496](https://pubmed.ncbi.nlm.nih.gov/40184496/). *Br J Dermatol*. [Review / Meta-Analysis]
Dotan A (2025). [PMID: 39931017](https://pubmed.ncbi.nlm.nih.gov/39931017/). *Harefuah*. [Review / Meta-Analysis]
Brokke KE (2025). [PMID: 40634186](https://pubmed.ncbi.nlm.nih.gov/40634186/). *Br J Anaesth*. [Review / Meta-Analysis]
AI-curated news mentioning cystic fibrosis-gastritis-megaloblastic anemia syndrome
Updated Aug 24, 2026
A recent study explores pediatric patients with cystic fibrosis and their perceptions of physical exercise programs. The findings highlight the importance of exercise in managing their condition, emphasizing positive attitudes among young patients.
A comprehensive review highlights the efficacy and access challenges of cystic fibrosis modulator therapies over the past year. The evolution of treatment strategies continues to impact patient outcomes significantly.
A clinical study explores the use of lung ultrasound in children with cystic fibrosis, providing insights into its potential as a diagnostic tool. The findings may enhance monitoring and management strategies for this patient population.
Cystic fibrosis (CF) is a genetic disorder that significantly impacts breathing and digestion. Awareness efforts continue to highlight the challenges faced by individuals living with this condition.
Sionna's cystic fibrosis drug failed a key trial, showing no significant additive effect when used with Vertex's Trikafta. This outcome surprised analysts and led to a sharp decline in Sionna's stock value.